title: Prolonged overall survival of patients with leptomeningeal carcinomatosis from nonsmall cell lung cancer.
abstract: Leptomeningeal metastasis (LM) carries a devastating prognosis. Treatment selection is limited for patients with LM. We introduced to use nimotuzumab (also known as h-R3) for treating LM of nonsmall cell lung cancer. Here, we report two patients in our treatment who had prolonged overall survival over 1 year each. The pressure of cerebrospinal fluid of the patients decreased remarkably after intrathecal therapy. Symptoms of the patients had been improved quickly after one or two times of intrathecal therapy. Nimotuzumab was well tolerated used in intrathecal therapy.
authors.affiliation: Department of Oncology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Yanfang
authors.initials: Y
authors.lastname: Ju
authors.affiliation: Department of Oncology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Shengjie
authors.initials: S
authors.lastname: Sun
authors.affiliation: Department of Oncology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Jinliang
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Oncology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Shunchang
authors.initials: S
authors.lastname: Jiao
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D014408:Biomarkers, Tumor; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D055756:Meningeal Carcinomatosis / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary*; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C501466:nimotuzumab